Study of TQB2303 in Patients With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
Multicenter, Randomized, Double-blind, Parallel Controlled, Phase III Clinical Study to Compare the Efficacy and Safety of TQB2303 in Conbination With CHOP Regimen (T-CHOP) Versus Rituximab in Combination With CHOP Regimen (R-CHOP) in Previously Untreated Subjects With CD20-Positive Diffuse Large B-cell Lymphoma (DLBCL)
Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
A PHASE3 clinical study on Diffuse Large B-cell Lymphoma, this trial is ongoing. The trial is conducted by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and has accumulated 8 data snapshots since 2019. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Dec 2025 — Present [monthly]
Unknown PHASE3
-
Sep 2025 — Dec 2025 [monthly]
Unknown PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Oct 2021 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Recruiting → Unknown Status
▶ Show 3 earlier versions
-
Jan 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Jun 2019 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2019 — Jun 2019 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Baoji, China , Changsha, China , Chengdu, China , Chongqing, China , Fuzhou, China , Haerbin, China , Kunming, China , Lanzhou, China , Liuchow, China , Nanchang, China and 12 more locations